title: A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.
abstract: OBJECTIVE
  A Phase II trial of bevacizumab plus tandutinib.
  
  
  METHODS
  We enrolled 41 recurrent, bevacizumab-naive glioblastoma patients for a trial of bevacizumab plus tandutinib. Median age was 55 and 71% were male. Treatment consisted of tandutinib 500 mg two-times a day (b.i.d.) and bevacizumab 10 mg/kg every 2 weeks starting day 15. Of 37 (90%) evaluable, nine (24%) had partial response.
  
  
  CONCLUSIONS
  Median overall and progression-free survival was 11 and 4.1 months; progression-free survival at 6 months was 23%. All patients suffered treatment-related toxicities; common grade ≥3 toxicities were hypertension (17.1%), muscle weakness (17.1%), lymphopenia (14.6%) and hypophosphatemia (9.8%). Four of six with grade ≥3 tandutinib-related myasthenic-like muscle weakness had electromyography-proven neuromuscular junction pathology. Tandutinib with bevacizumab was as effective but more toxic than bevacizumab monotherapy.
authors: Neuro-Oncology Division, Neurological Institute of New York, Columbia University College of Physicians & Surgeons, 710 West 168th Street, 9th Floor, New York, NY 10032, USA.
authors: Yazmin
authors: Y
authors: Odia
authors: US FDA, 10903 New Hampshire Ave, Bldg WO22 Rm 2331, Silver Spring, MD 20993, USA.
authors: Joohee
authors: J
authors: Sul
authors: Biometric Research Branch, Division of Cancer Treatment & Diagnosis, NCI, 9609 Medical Center Drive, Room 5W124, Rockville, MD 20850, USA.
authors: Joanna H
authors: JH
authors: Shih
authors: Neuro-Oncology Division, Neurological Institute of New York, Columbia University College of Physicians & Surgeons, 710 West 168th Street, 9th Floor, New York, NY 10032, USA.
authors: Teri N
authors: TN
authors: Kreisl
authors: Department of Radiology, National Institutes of Health Clinical Center, Building 10, Clinical Center 10 Center Drive, MSC 1074, Bethesda, MD 20892, USA.
authors: John A
authors: JA
authors: Butman
authors: Neuro-Oncology Division, Neurological Institute of New York, Columbia University College of Physicians & Surgeons, 710 West 168th Street, 9th Floor, New York, NY 10032, USA.
authors: Fabio M
authors: FM
authors: Iwamoto
authors: Division of Neuro-Oncology, Director of the Brain Tumor Center, New York-Presbyterian Hospital/Weill Cornell Medical Center, 1305 York Avenue, 9th Floor, New York, NY 10021, USA.
authors: Howard A
authors: HA
authors: Fine
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D010879:Piperazines; D011799:Quinazolines; D000068258:Bevacizumab; C464670:tandutinib
keywords: bevacizumab; glioblastoma; tandutinib